Risks and benefits of replacement estrogen

Area of Science:

• Reproductive endocrinology
• Cardiovascular disease prevention
• Oncology

Background:

• Observational studies suggest unopposed oral estrogen reduces coronary events by ~50% in postmenopausal women.
• Hormone replacement therapy (HRT) is associated with a ~50% reduction in hip fracture after 3+ years of use.

Purpose of the Study:

• To review the benefits and risks of unopposed oral estrogen in postmenopausal women.
• To evaluate the impact of estrogen on cardiovascular health, bone density, and cancer risk.

Main Methods:

• Review of existing observational studies on hormone replacement therapy.
• Analysis of reported outcomes including coronary events, hip fractures, and cancer incidence.

Main Results:

• Unopposed oral estrogen shows a 50% reduction in coronary events and hip fractures.
• Increased risk of endometrial cancer proportional to duration of use, persisting after discontinuation.
• Potential 50% increase in breast cancer risk with >5 years of estrogen use, requiring further investigation to exclude bias.

Conclusions:

• While estrogen offers cardiovascular and bone benefits, significant cancer risks necessitate caution.
• Lack of clinical trial data on estrogen-progestin use prevents universal recommendations for HRT type and duration.